COMBINATION THERAPY OF MESENCHYMAL STROMAL CELLS AND INFLIXIMAB IN UNCOMPLICATED (LUMINAL) CROHN DISEASE

AIMS. To investigate the efficacy of combination therapy using bone marrow-derived mesenchymal stromal cells (MSC) and Infliximab (IFX) to achieve «deep remission» in patients with luminal Crohn disease (CD). METHODS. Our study included 72 patients (19-62 y old) (Ме=29) with luminal CD. Patients ini group (n=21) received standard 5-aminosalicylic acid (5-ASA) and glucocorticosteroids (GCS) therapy in combination with MSC. Patients in 2 group (n=32) were prescribed anti-cytokine therapy IFX. Patients in 3 group (n=19) received MSC and IFX. RESULTS. Clinical, immunobiological and hystological results (C-reactive protein-CRP, fecal calprotectin-FCP, Gebs scale) showed more significant decrease of local and systemic inflammation activity in 3 group of patients. During 3-year follow-up we observed the longer duration of remission in patients, received MSC and IFX compared to 1 group of patients (р=0,04) and 2 group of patients (р=0,038). CONCLUSIONS. Combination therapy of bone marrow-derived MSC and IFL provides «deep remission» in patients with luminal CD and has higher prognostic value in duration of CD remission period.

Crohn's disease, inflammatory bowel disease, infliximab, mesenchymal stromal cells

1. Воробьев Г.И., Халиф И.Л. Неспецифические воспалительные заболевания кишечника. Миклош, 2008.

2. Pineton de Chambrun G., Peyrin-Biroulet L., Lémann M. et al. Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. Hepatol. - 2010. - vol. 7. - № 1. -p. 15-29.

3. Lichtenstein G.R., Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflammatory Bowel Diseases. - 2010. - 16: 338-346. doi: 10.1002/ ibd.20997.

4. Froslie K.F., Jahnsen J., Moum B.A. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. - 2007. - vol. 133. - № 2. -p. 412-422.

5. Colombel J., Rutgeerts P., Sandborn W.J. et al. Deep remission predicts long-term outcomes for adalimumab-treated patients with Crohn’s disease: data from EXTEND. Gut. - 2010. - vol. 59. - Suppl. 3. -p. A80. Abstract OP371.

6. Colombel J., Rutgeerts P., Sandborn W.J. et al. Deep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn’s disease: results from EXTEND. J. Crohn’s Colitis. - 2010. - vol. 4. -P. S11. Abstract OP31.

7. Zallot C., Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. - 2013 Mar; 15 (3): 315. doi: 10.1007/s11894-013-0315-7.

8. Князев О.В., Парфенов А.И., Щербаков П.Л. и соавт. Клеточная терапия рефрактерных форм болезни Крона. Клеточные технологии в биологии и медицине. - 2013. № 3. - с. 145-152.

9. Duijvestein M., Molendijk I., Roelofs H. et al. Mesenchymal stromal cell function is not affected by drugs used in the treatment of inflammatory bowel disease. Cytotherapy. - 2011 Oct; 13 (9): 1066-73.

10. Huang H.R., Zan H., Lin Y. et al. Effects of azathioprine and infliximab on mesenchymal stem cells derived from the bone marrow of rats in vitro. Mol. Med. Rep. - 2014, Mar; 9 (3): 1005-12. doi: 10.3892/mmr.2014.1905.

11. Цыб А.Ф., Коноплянников А.Г., Колесникова А.И. и соавт. Получение и использование в медицине клеточных культур из мезенхимальных стволовых клеток костного мозга человека. Вестник Российской Академии медицинских наук. - 2004. - № 59 (9). - с. 71-76.

12. Best W.R., Becktel J.M., Singleton J.W. et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. - 1976. - vol. 70. - p. 439-444.

13. Geboes K., Riddel R., Jensfelt B. et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. - 2000; 47: 404-409.

14. Kaplan E.I., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. -1958; 53: 457.

15. Das M., Sundell I.B., Koka P.S. Adult mesenchymal stem cells and their potency in the cellbased therapy. J. Stem. Cells. - 2013. 8. (1). 1-16.

16. Baert F.J., D’Haens G.R., Peeters M. et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly downregulates the inflammation in Crohn’s ileocolitis. Gastroenterology. - 1999; 116 (1): 22-28.

17. Watkins P.E., Warren B.F., Stephens S. et al. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut. -1997; 40 (5): 628-633.

18. Najar M., Raicevic G., Fayyad-Kazan H. et al. Mesenchymal stromal cells and immunomodulation: A gathering of regulatory immune cells. Cytotherapy. -2016 Feb; 18 (2): 160-71. doi: 10.1016/j.jcyt.2015.10.011. Review.